Cholinergic Drugs Global Market Report 2024

Cholinergic drugs are medications that imitate or enhance the effects of acetylcholine, a neurotransmitter in the nervous system. These drugs primarily target cholinergic receptors to activate the parasympathetic nervous system, resulting in physiological responses such as increased salivation, muscle contraction, and a slowed heart rate.

Cholinergic drugs come in several forms, including powder, tablet, and capsule. Powder formulations, which are finely ground substances, can be taken orally, usually mixed with liquids, or applied topically. The types of cholinergic drugs include muscarinic agonists, nicotinic agonists, and acetylcholinesterase inhibitors. They are used for various conditions such as Alzheimer's disease, myasthenia gravis, glaucoma, overactive bladder, and schizophrenia, and are available in settings such as hospital pharmacies and retail pharmacies.

The cholinergic drugs market research report is one of a series of new reports that provides cholinergic drugs market statistics, including cholinergic drugs industry global market size, regional shares, competitors with a cholinergic drugs market share, detailed cholinergic drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the cholinergic drugs industry. This cholinergic drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cholinergic drugs market size has grown steadily in recent years. It will grow from $7.56 billion in 2023 to $7.83 billion in 2024 at a compound annual growth rate (CAGR) of 3.7%. The growth observed during the historic period can be credited to the increasing aging population, regulatory approvals, rising healthcare expenditure, and ongoing research and development efforts.

The cholinergic drugs market size is expected to see steady growth in the next few years. It will grow to $9.21 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth during the forecast period is expected to be driven by expanding applications, economic growth in emerging markets, increased awareness and diagnosis, regulatory developments, and the rising prevalence of chronic diseases. Key trends in the forecast period include technological advancements, a preference for sustainable and eco-friendly products, the development of advanced cholinergic drugs with fewer side effects, a rise in R&D activities for drugs, and technological innovation.

The increasing prevalence of neurological and psychiatric disorders is anticipated to drive the growth of the cholinergic drugs market in the future. Neurological disorders are medical conditions affecting the nervous system, including the brain, spinal cord, and nerves. Psychiatric disorders are mental health conditions impacting a person's mood, thinking, and behavior. The prevalence of these disorders is due to a mix of genetic, biological, environmental, and psychological factors that disrupt normal brain function and mental processes. Cholinergic drugs aid in treating neurological and psychiatric disorders by enhancing or mimicking the action of acetylcholine, improving neurotransmission, and alleviating symptoms related to conditions such as Alzheimer's disease, myasthenia gravis, and various mood and anxiety disorders. For example, in May 2024, the National Center for Biotechnology Information, a US-based Library of Medicine, estimated that the number of Americans aged 65 and older living with Alzheimer's disease is expected to rise from 6.9 million in 2024 to nearly 13 million by 2050. Additionally, in 2024, the National Alliance On Mental Illness, a US-based organization, reported that psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations each year among U.S. individuals aged 18-44. Thus, the increasing prevalence of neurological and psychiatric disorders is fueling the growth of the cholinergic drugs market.

The growing prevalence of chronic diseases is projected to drive the expansion of the cholinergic drugs market in the future. Chronic disease refers to a long-lasting condition that typically requires ongoing medical attention and can limit daily activities or quality of life. The prevalence of chronic disease is due to altered habits, genetic factors, and exposure to chemicals, toxins, and pollutants in the air. Cholinergic drugs help manage chronic diseases by targeting specific pathways involved in the disease process, alleviating symptoms, and improving the quality of life for affected individuals. For instance, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based medicine library, reported that the number of people aged 50 and above suffering from one or more chronic illnesses is expected to increase by 99.5% by 2050, from 71.52 million in 2020 to 142.66 million. Therefore, the increased prevalence of chronic diseases is driving the growth of the cholinergic drugs market.

Leading companies in the cholinergic drugs market are developing innovative products, such as neostigmine methylsulfate injection, to maintain their market position. Neostigmine methylsulfate injection is a cholinesterase inhibitor that enhances cholinergic activity by preventing the breakdown of acetylcholine. For example, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced a Neostigmine Methylsulfate Injection USP in a prefilled syringe. This 3mg/3mL prefilled syringe (PFS) was launched in the United States and acts as a cholinesterase inhibitor. It is specifically used to reverse the effects of nondepolarizing neuromuscular blocking agents (NMBAs) following surgical procedures. This innovative product offers a range of unique features designed to improve the efficiency, accuracy, and safety of administering Neostigmine Methylsulfate. Prefilled syringes provide unmatched convenience by eliminating the need for manual filling, reducing preparation time for healthcare professionals, and minimizing the potential for dosage errors.

Major companies operating in the cholinergic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Abbvie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Company Limited, UCB S.A., Sun Pharmaceutical Industries Ltd., Eisai Pharmaceutical Co. Ltd., Aurobindo Pharma Limited, Ono Pharmaceutical Co. Ltd., Hikma Pharmaceuticals plc, Lupin Limited, H Lundbeck A/S, Alvogen Inc., Mylan N.V., Nicox S.A, Allergan India Private Limited.

North America was the largest region in the cholinergic drugs market in 2023. The regions covered in the cholinergic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cholinergic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cholinergic drugs market consists of sales of cholinesterase inhibitors, direct cholinergic agonists, muscarinic agonists, nicotinic agonists, and anticholinesterases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.